BMRA
Biomerica, Inc.
BMRA lost money over the past year, so it has no meaningful PE right now. Analysts expect losses to grow.
BMRA Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Weak | |
| Weak | |
| Unavailable |
BMRA's revenue is currently stable, but its profitability and cash flow are weak. There isn't enough data to rate its balance sheet.
BMRA PE Valuation
BMRA has no meaningful PE right now: it lost money over the past year.
BMRA Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| Strong decline | |
| -- | |
| Limited | |
| High |
Analysts expect BMRA's losses to grow, with revenue declining.
BMRA Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$1.67 | -$0.15 |
| Q2 2026 | -$1.30 | +$0.86 |
| Q1 2026 | -$1.45 | +$0.87 |
| Q4 2025 | -$1.49 | +$1.23 |
| Q3 2025 | -$1.52 | +$1.44 |
| Q2 2025 | -$2.16 | +$0.72 |
| Q1 2025 | -$2.32 | +$0.64 |
| Q4 2024 | -$2.72 | +$0.32 |
BMRA is still losing money, but far less than before: $1.67 per share over the past year, against $4.96 at its worst in mid-2021.
BMRA Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $1.3M | -8.3% |
| Q2 2026 | $875K | +17% |
| Q1 2026 | $987K | -12% |
| Q4 2025 | $1.2M | -26% |
| Q3 2025 | $1.4M | -24% |
| Q2 2025 | $749K | -33% |
| Q1 2025 | $1.1M | +10% |
| Q4 2024 | $1.6M | +4.4% |
BMRA's revenue has slid since its 2022 peak: $1M last quarter, down 8.3% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -97% | -16 points |
| Q2 2026 | -175% | +34 points |
| Q1 2026 | -132% | -23 points |
| Q4 2025 | -113% | -53 points |
| Q3 2025 | -81% | -5.3 points |
| Q2 2025 | -209% | -72 points |
| Q1 2025 | -108% | +89 points |
| Q4 2024 | -61% | +42 points |
BMRA's operating margin was −97% last quarter, down 16 points from the same quarter a year ago.
BMRA Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$802K | -$534K |
| Q2 2026 | -$912K | -$251K |
| Q2 2025 | -$661K | +$407K |
| Q2 2024 | -$1.1M | -$105.2K |
| Q1 2024 | -$1.8M | -$70.4K |
| Q4 2023 | -$848K | +$389.7K |
| Q3 2023 | -$1.7M | -$88.1K |
| Q2 2023 | -$962.8K | +$3.3M |
BMRA has burned cash in almost every quarter: −$4M over the past year, against −$4M the year before.
BMRA Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +9.5% | +286K shares |
| 1 year | +43% | +999K shares |
| 3 years | +86% | +1.5M shares |
| 5 years | +121% | +1.8M shares |
| Available history | +169% | +2.1M shares |
BMRA has 3M diluted shares, up 43% from a year ago.
BMRA Net Leverage
BMRA's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
BMRA Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 34.0 | Neutral |
| Stochastic | 10.9 | Oversold |
BMRA's weekly RSI is 34 (neutral) and its Stochastic is 11 (oversold).
BMRA PE vs Healthcare Sector
BMRA has no meaningful PE right now: it lost money over the past year.
BMRA Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.81 | 28% below |
| 20 week MA | $1.83 | 29% below |
| 50 week MA | $2.08 | 38% below |
| 100 week MA | $2.83 | 54% below |
| 200 week MA | $5.62 | 77% below |
BMRA is in a downtrend: it's below all five of its weekly moving averages, and 77% below its 200-week average.
BMRA Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $21.6 | $39.8 | +84% |
| 2021 | $39.8 | $33.6 | -15% |
| 2022 | $33.6 | $29.7 | -12% |
| 2023 | $29.7 | $10.0 | -66% |
| 2024 | $10.0 | $2.52 | -75% |
| 2025 | $2.52 | $2.70 | +7.1% |
| 2026 YTD | $2.70 | $1.30 | -52% |
BMRA has finished lower in four of the last six years. It's down 52% so far in 2026.